Lenalidomide Zentiva

Lenalidomide, the active ingredient in Lenalidomide Zentiva, is an immunomodulatory drug (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in combination therapy.

GNH USA supplies Lenalidomide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomide is used in hematologic malignancies and related disorders, targeting abnormal plasma‑cell proliferation and dysplastic marrow. - Multiple myeloma: improves response rates and progression‑free survival when combined with standard regimens. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and can induce cytogenetic remission. - Mantle cell lymphoma (in combination therapy): contributes to disease control as part of multi‑agent treatment.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: decreased neutrophil count increasing infection risk. - Thrombocytopenia: reduced platelet count leading to bleeding tendencies. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require supportive care. - Rash: skin irritation or erythema. - Nausea: upset stomach often mild to moderate.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: profound immune suppression. - Severe thrombocytopenia: high bleeding risk. - Secondary primary malignancies: emergence of new cancers. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions. - Hepatic failure: marked liver enzyme elevations or dysfunction.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor laboratory parameters. - Blood count monitoring: perform complete blood counts regularly to detect cytopenias. - Thromboembolic risk assessment: consider prophylactic anticoagulation in high‑risk patients. - Pregnancy avoidance: Lenalidomide is contraindicated in pregnancy; enforce strict contraception. - Renal function adjustment: dose may need modification in patients with impaired renal clearance. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lenalidomide can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide exposure. - Anticoagulants (e.g., warfarin): heightened risk of bleeding. - Live vaccines: reduced efficacy and potential infection risk. - Thalidomide or pomalidomide: additive teratogenicity and overlapping toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may lower drug levels. - NSAIDs: increase risk of gastrointestinal bleeding when combined with anticoagulation. - CYP2C19 inhibitors (e.g., fluoxetine): modest effect on metabolism requiring observation.